Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 19

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 19
---
 protection. Even if we are able
to obtain patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing
with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar
or alternative technologies or products in a non-infringing manner. We may also fail to take the required actions or pay the necessary
fees to maintain our patents.

Moreover, any of our pending
applications may be subject to a third party pre-issuance submission of prior art to the U. S. Patent and Trademark Office, or USPTO, the
European Patent Office, or EPO, the Intellectual Property Office in the United Kingdom, the Australian Patent and Trademark Office and/or
any patents issuing thereon may become involved in opposition, derivation, reexamination, post grant review, interference proceedings
or other patent office proceedings or litigation, in the United States or elsewhere, challenging our patent rights. An adverse determination
in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, and allow third parties
to commercialize our technology or products and compete directly with us, without payment to us. In addition, if the breadth or strength
of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to
exploit our intellectual property or develop or commercialize current or future drug candidates.

The issuance of a patent is
not conclusive as to the inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices
in the United States, the European Union, Australia and elsewhere. Such challenges may result in loss of ownership or in patent claims
being narrowed, invalidated or held unenforceable, in whole or in part, which could limit the duration of the patent protection of our
technology and products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours.

In addition, other companies
may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may
require us to allocate significant resources to preventing such circumvention. Such developments could enable other companies to circumvent
our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the European Union, Australia and
in other jurisdictions. Such developments may also require us to allocate significant